Synthesis, in vitro assays, molecular docking, theoretical ADMET prediction, and evaluation of 4-methoxy-phenylthiazole-2-amine derivatives as acetylcholinesterase inhibitors
- 42 Downloads
Based on the cholinergic hypothesis of the reported compound, N-(4-(4-methoxy-phenyl)thiazol-2-yl)-3-(pyrrolidin-1-yl)propionamide, which had a good inhibitory activity to acetylcholinesterase (AChE), the new 4-methoxy-phenylthiazole-2-amine derivatives as AChE inhibitors (AChEIs) have been designed and synthesized in this study. Their chemical structures were confirmed by proton nuclear magnetic resonance, carbon-13 nuclear magnetic resonance, mass spectrometry, and infrared. Furthermore, their inhibitory activities against AChE in vitro were also tested by Ellman spectrophotometry, and the inhibitory activity test results showed that most of the compounds of 4-methoxy-phenylthiazole-2-amine derivatives had a certain AChE inhibitory activity in vitro, and the IC50 (half-maximal inhibitory concentration) value of compound 5g was 5.84 μmol/L, which was higher than that of the reference compound, rivastigmine. Moreover, it had almost no inhibitory effect on butyrylcholinesterase. In addition, compound 5g was subjected to enzyme inhibition kinetics experiments, and the result of Lineweaver–Burk’s V−1–[S]−1 double-reciprocal plot showed that the acting type of compound 5g was mixed inhibition type. Furthermore, the AChE inhibitory activity mechanism of compound 5g was explored by the conformational analysis and molecular docking, which was based on the principle of the four-point pharmacophore model necessary for AChE inhibition. Finally, in silico molecular property and ADMET (absorption, distribution, metabolism, excretion, and toxicity) of the synthesized compounds were predicted by using Molinspiration and PreADMET online servers, respectively. It can be concluded that the lead AChEI compound 5g presented satisfactory drug-like characteristics and ADME properties.
KeywordsAcetylcholinesterase (AChE) Phenylthiazole Molecular docking AutoDock ADMET
This work was supported by grants from Natural Science Foundation of Hebei Province (No. H2017201075).
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflict of interest.
- Bag S, Tulsan R, Sood A, Datta S, Torok M (2013) Pharmacophore modeling, virtual and in vitro screening for acetylcholinesterase inhibitors and their effects on amyloid-β self- assembly. Curr Comput Aided Drug Des 9:2–14Google Scholar
- Zhong F, Xing J, Li X, Liu X, Fu Z, Xiong Z, Lu D, Wu X, Zhao J, Tan X, Li F, Luo X, Li Z, Chen K, Zheng M, Jiang H (2018) Artificial intelligence in drug design Sci China Life Sci 61:59–72Google Scholar
- Abbas-Mohammadi M, Moridi Farimani M, Salehi P, Nejad Ebrahimi S, Sonboli A, Kelso C, Skropeta D (2018) Acetylcholinesterase-inhibitory activity of Iranian plants: combined HPLC/bioassay-guided fractionation, molecular networking and docking strategies for the dereplication of active compounds. J Pharm Biomed 158:471–479CrossRefGoogle Scholar
- Ma ZY, Yang Q, Zhang YG, L JJ, Yang GL (2014) Design, synthesis and evaluation of N-acyl-4-phenylthiazole-2-amines as acetylcholinesterase inhibitors. Acta Pharm Sin 49:813–818Google Scholar
- Tian YF, Chen JT, Li JJ, Zhang YC, Cao TT, Ma ZY (2015) Design, synthesis and evaluation of new l-proline as acetylcholinesterase inhibitors. Acta Pharm Sin 50:719–724Google Scholar
- Tripathi RKP, M Sasi V, Gupta SK, Krishnamurthy S, Ayyannan SR (2018) Design, synthesis, and pharmacological evaluation of 2-amino-5-nitrothiazole derived semicarbazones as dual inhibitors of monoamine oxidase and cholinesterase: effect of the size of aryl binding site. J Enzyme Inhib Med Chem 33:37–57CrossRefGoogle Scholar